PRCT002 PRostate Cancer Treatment With the AQUABEAM Robotic System
Study Phase: N/A
Recruitment Status: Recruiting
Start Date: December 15, 2023
End Date: April 01, 2025
Inclusion Criteria:
- Clinical Stage ≤ T2c
- PSA ≤ 20 ng/ml
- Prostate volume ≥ 30 ml
- Grade Group (GG) 1 or 2: If GG 1: ≥ 3 cores positive for cancer. Note, multiple positive from any MRI targeted lesion will be considered as a single positive core.
Exclusion Criteria:
- Any prior or current treatment for prostate cancer, including but not limited to surgery, radiation therapy (external or brachytherapy), tissue ablation or chemotherapy.
- Patients with previous surgical or minimally invasive treatment of benign prostatic hyperplasia within the prior 12 months.
- Radiographically suspicious lymph node involvement confirmed with biopsy or PET scan.
- Evidence of bone metastasis.
- Evidence of extracapsular involvement.
- Evidence of seminal vesicle invasion on DRE or MRI read as "definite", "probable" or "consistent with"
- Any condition or history of illness or surgery that may pose an additional risk to men undergoing the Aquablation procedure.
-
Conditions:
- Prostatic Neoplasms